{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:48:57Z","timestamp":1792838937487,"version":"4.5.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ymthe.2024.07.016","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T12:35:14Z","timestamp":1721651714000},"page":"3220-3259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders"],"prefix":"10.1016","volume":"32","author":[{"given":"Besarte","family":"Vrellaku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilda","family":"Sethw Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Howitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Harriss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser","family":"McBlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Schettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Lion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Mindur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Duerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimoun","family":"Azzouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.07.016_bib1","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/S0140-6736(05)77740-0","article-title":"Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus","volume":"351","author":"Wagner","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.07.016_bib2","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1089\/10430349950016384","article-title":"A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis","volume":"10","author":"Zuckerman","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","article-title":"AAV gene therapy for Tay-Sachs disease","volume":"28","author":"Flotte","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib4","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1126\/science.286.5448.2244","article-title":"Gene therapy death prompts review of adenovirus vector","volume":"286","author":"Marshall","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.07.016_bib5","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ymthe.2020.01.006","article-title":"Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial","volume":"28","author":"Somanathan","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib7","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of Voretigene NEPARVOVEC (AAV2-hrpe65v2) in patients with RPE65 -mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2024.07.016_bib9","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.07.016_bib10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/mt.2009.277","article-title":"Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration","volume":"18","author":"Simonelli","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib16","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib17","series-title":"Sarepta Therapeutics announces FDA approval of ELEVIDYS, the first gene\u00a0therapy to treat Duchenne muscular dystrophy","year":"2023"},{"key":"10.1016\/j.ymthe.2024.07.016_bib18","series-title":"FDA approves first gene therapy for treatment of certain patients with\u00a0Duchenne muscular dystrophy","year":"2023"},{"key":"10.1016\/j.ymthe.2024.07.016_bib19","doi-asserted-by":"crossref","first-page":"809118","DOI":"10.3389\/fmed.2021.809118","article-title":"Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings","volume":"8","author":"Au","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib20","doi-asserted-by":"crossref","first-page":"113324","DOI":"10.1016\/j.biopha.2022.113324","article-title":"Gene therapy clinical trials, where do we go? An overview","volume":"153","author":"Arabi","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2024.07.016_bib21","first-page":"1276","article-title":"A systematic review of adeno-associated virus gene therapies in neurology: The need for consistent safety monitoring of a promising treatment","volume":"93","author":"Horton","year":"2022","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2024.07.016_bib22","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.nmd.2023.09.008","article-title":"261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, the Netherlands","volume":"33","author":"Servais","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2024.07.016_bib23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (sunfish part 2): A phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib24","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib25","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.07.016_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series","volume":"231","author":"Chand","year":"2021","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ymthe.2024.07.016_bib27","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1503\/cmaj.160142","article-title":"Thrombotic microangiopathies: A general approach to diagnosis and management","volume":"189","author":"Arnold","year":"2017","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.ymthe.2024.07.016_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2024.07.016_bib29","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IGG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib30","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-023-05948-2","article-title":"Adeno-associated virus 2 infection in children with non-A-E hepatitis","volume":"617","author":"Ho","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.07.016_bib32","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41586-023-06003-w","article-title":"Genomic investigations of unexplained acute hepatitis in children","volume":"617","author":"Morfopoulou","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.07.016_bib33","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41586-023-05949-1","article-title":"Adeno-associated virus type 2 in US children with acute severe hepatitis","volume":"617","author":"Servellita","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.07.016_bib34","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"Li","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib36","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2024.07.016_bib37","doi-asserted-by":"crossref","first-page":"6817","DOI":"10.1128\/JVI.00278-09","article-title":"Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in\u00a0vivo","volume":"83","author":"Li","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib38","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of lid in hemophilia by Aav-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","article-title":"Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.07.016_bib40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/vir.0.035113-0","article-title":"Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5","volume":"93","author":"Harbison","year":"2012","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib41","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1128\/JVI.74.19.9281-9293.2000","article-title":"Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection","volume":"74","author":"Wobus","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2014.00009","article-title":"Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors","volume":"5","author":"Tseng","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib43","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib44","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib45","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype RH.10 carrying human sgsh and sumf1 cdnas in children with mucopolysaccharidosis type IIIA disease: Results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/intimm\/dxr048","article-title":"Corticosteroids shift the Toll-like receptor response pattern of primary-isolated murine liver cells from an inflammatory to an anti-inflammatory state","volume":"23","author":"Broering","year":"2011","journal-title":"Int. Immunol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib49","doi-asserted-by":"crossref","first-page":"655478","DOI":"10.3389\/fimmu.2021.655478","article-title":"Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome","volume":"12","author":"Gougeon","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib50","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1089\/hum.2021.135","article-title":"Intracerebral Gene therapy in four children with sanfilippo B syndrome: 5.5-year follow up results","volume":"32","author":"Deiva","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib51","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1016\/j.transproceed.2019.08.039","article-title":"Inhibition of T Helper Cell Differentiation by Tacrolimus or Sirolimus Results in Reduced B-Cell Activation: Effects on T Follicular Helper Cells","volume":"51","author":"Kraaijeveld","year":"2019","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.ymthe.2024.07.016_bib52","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JND-190426","article-title":"Advancements in AAV-mediated Gene Therapy for Pompe Disease","volume":"7","author":"Salabarria","year":"2020","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.07.016_bib54","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.3390\/jcm10235540","article-title":"Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I","volume":"10","author":"Mirea","year":"2021","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib55","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/biom13101484","article-title":"Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic RPE65-Mediated Inherited Retinal Dystrophies in a Cohort of Patients from a Single Center","volume":"13","author":"Kiraly","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2024.07.016_bib56","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib57","doi-asserted-by":"crossref","first-page":"1167762","DOI":"10.3389\/fcell.2023.1167762","article-title":"Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy","volume":"11","author":"Mendell","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib58","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib59","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5\u2013factor VIII gene transfer in severe hemophilia a","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib60","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib61","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: A long journey to successful Gene Transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib62","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne's Muscular Dystrophy","volume":"388","author":"B\u00f6nnemann","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib63","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor ix administered with prophylactic glucocorticoids in patients with haemophilia B: A single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2022.08.009","article-title":"A first-in-human phase I\/IIA gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2","volume":"27","author":"Flanigan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.07.016_bib65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JND-200593","article-title":"Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience","volume":"8","author":"Friese","year":"2021","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.07.016_bib66","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of Raavrh74.mhck7.micro-dystrophin in children with Duchenne muscular dystrophy","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib67","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","article-title":"Early phase clinical immunogenicity of Valoctocogene Roxaparvovec, an AAV5-mediated gene therapy for hemophilia A","volume":"29","author":"Long","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hfix activity achieved after single AAV5-hfix treatment in hemophilia B patients and nhps with pre-existing Anti-AAV5 Nabs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.07.016_bib69","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due torpe65mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal Onasemnogene Abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: Phase I ascending-dose study (strong)","volume":"10","author":"Finkel","year":"2023","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.07.016_bib71","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.ymthe.2021.02.013","article-title":"Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I\/IIA gene therapy trial","volume":"29","author":"Mishra","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib72","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1172\/JCI70314","article-title":"Human Treg responses allow sustained recombinant adeno-associated virus\u2013mediated transgene expression","volume":"123","author":"Mueller","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.07.016_bib73","doi-asserted-by":"crossref","first-page":"e143780","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.07.016_bib74","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with CHOROIDEREMIA: Initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2024.07.016_bib75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/hum.2018.098","article-title":"Age-related seroprevalence of antibodies against AAV-LK03 in a UK population cohort","volume":"30","author":"Perocheau","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib76","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/mt.2009.245","article-title":"The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques","volume":"18","author":"Wang","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib78","unstructured":"Guideline on the Quality, Non-clinical and Clinical Aspects of Gene Therapy Medicinal Products. (EMA\/CAT\/80183\/2014). European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-non-clinical-aspects-gene-therapy-medicinal-products_en.pdf. accessed date August 02, 2024."},{"key":"10.1016\/j.ymthe.2024.07.016_bib79","unstructured":"Center for Drug Evaluation and Research (no date) Guidance for Industry, U.S. Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug. accessed date August 02, 2024."},{"key":"10.1016\/j.ymthe.2024.07.016_bib80","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/978-3-030-03095-7_42","article-title":"Duchenne muscular dystrophy exon-skipping trials","author":"Mendell","year":"2019","journal-title":"Muscle Gene Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib81","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mrna and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib82","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: Potential impact of CPG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.07.016_bib83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24\u00a0months or younger and bodyweight up to 15\u00a0kg: an observational cohort study","volume":"6","author":"Wei\u00df","year":"2022","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.ymthe.2024.07.016_bib84","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 Year follow-up of a phase 1 randomised clinical trial","volume":"386","author":"Rakoczy","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.07.016_bib85","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with Valoctocogene Roxaparvovec in severe haemophilia a","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2024.07.016_bib86","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.07.016_bib87","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/01926233231202995","article-title":"Safety findings of dosing gene therapy vectors in NHP with pre-existing or treatment-emergent anti-capsid antibodies","volume":"51","author":"Chandra","year":"2023","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib88","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.3390\/biomedicines11082223","article-title":"Recent advancements in aav-vectored immunoprophylaxis in the nonhuman primate model","volume":"11","author":"Campbell","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2024.07.016_bib89","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.07.016_bib90","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Anti-inflammatory action of glucocorticoids \u2014 new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib91","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.ymthe.2024.07.016_bib92","doi-asserted-by":"crossref","first-page":"991832","DOI":"10.3389\/fimmu.2022.991832","article-title":"A versatile toolkit for overcoming AAV immunity","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib93","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ekir.2019.08.019","article-title":"Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease","volume":"4","author":"Oh","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymthe.2024.07.016_bib94","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/art.39537","article-title":"Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis","volume":"68","author":"Movahedi","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib95","doi-asserted-by":"crossref","first-page":"c54","DOI":"10.1159\/000097598","article-title":"Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases","volume":"105","author":"Uzu","year":"2007","journal-title":"Nephron. Clin. Pract."},{"key":"10.1016\/j.ymthe.2024.07.016_bib96","doi-asserted-by":"crossref","first-page":"999021","DOI":"10.3389\/fimmu.2022.999021","article-title":"Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood","volume":"13","author":"Smith","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib97","doi-asserted-by":"crossref","first-page":"672449","DOI":"10.3389\/fimmu.2021.672449","article-title":"Effect of CPG depletion of Vector Genome on CD8+ T\u00a0cell responses in Aav Gene therapy","volume":"12","author":"Bertolini","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib98","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/jth.14740","article-title":"Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors","volume":"18","author":"Doshi","year":"2020","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2024.07.016_bib99","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3389\/fimmu.2020.01293","article-title":"B cell depletion eliminates FVIII memory B cells and enhances AAV8-Cof8 immune tolerance induction when combined with rapamycin","volume":"11","author":"Biswas","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib100","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm.2019.05.56","article-title":"Pompe disease gene therapy: Neural manifestations require consideration of CNS directed therapy","volume":"7","author":"Byrne","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib101","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6","article-title":"Technical Supplement to Chapter 4: Searching for and selecting studies","author":"Lefebvre","year":"2019"},{"key":"10.1016\/j.ymthe.2024.07.016_bib102","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/mt.2011.237","article-title":"Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector","volume":"20","author":"Bowles","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib103","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib104","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.2022018971","article-title":"Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1\/2 Alta study","volume":"143","author":"Leavitt","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.07.016_bib105","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib106","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.07.016_bib107","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajo.2022.02.023","article-title":"Leber Hereditary Optic Neuropathy Gene Therapy: Adverse Events and Visual Acuity Results of All Patient Groups","volume":"241","author":"Lam","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib108","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ophtha.2016.03.003","article-title":"Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy","volume":"123","author":"Weleber","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2024.07.016_bib109","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/acn3.51519","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy","volume":"9","author":"D'Silva","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaophthalmol.2022.6254","article-title":"Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations","volume":"141","author":"von Krusenstiern","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib111","doi-asserted-by":"crossref","first-page":"100817","DOI":"10.1016\/j.lanepe.2023.100817","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.ymthe.2024.07.016_bib112","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry","volume":"11","author":"Servais","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.07.016_bib113","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41434-022-00341-6","article-title":"Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study","volume":"30","author":"Bitetti","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib114","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2739\/kurumemedj.MS6934008","article-title":"Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1","volume":"69","author":"Nanri","year":"2024","journal-title":"Kurume Med. J."},{"key":"10.1016\/j.ymthe.2024.07.016_bib115","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/a-1538-4936","volume":"234","author":"Witte","year":"2022","journal-title":"Klin. Padiatr."},{"key":"10.1016\/j.ymthe.2024.07.016_bib116","doi-asserted-by":"crossref","DOI":"10.3233\/JND-221659","article-title":"Repeated AAV9 Titer Determination in a Presymptomatic SMA Patient with Three SMN2 Gene Copies - A Case Report","author":"Eisenk\u00f6lbl","year":"2024","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.07.016_bib117","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/00185787231182562","article-title":"Onasemnogene Abeparvovec: Post-infusion Efficacy and Safety in Patients With Spinal Muscular Atrophy (SMA)\u2014A Fondazione Policlinico Gemelli IRCCS Experience","volume":"59","author":"Favia","year":"2024","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.ymthe.2024.07.016_bib118","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nmd.2023.11.010","article-title":"Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio","volume":"34","author":"Waldrop","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2024.07.016_bib119","doi-asserted-by":"crossref","first-page":"e20200729","DOI":"10.1542\/peds.2020-0729","article-title":"Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2024.07.016_bib120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.sleep.2023.09.019","article-title":"Sleep disordered breathing in infants identified through newborn screening with spinal muscular atrophy","volume":"111","author":"Chiang","year":"2023","journal-title":"Sleep Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib121","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1136\/archdischild-2023-325788","article-title":"Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec","volume":"108","author":"Beri","year":"2023","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ymthe.2024.07.016_bib122","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/mus.27926","article-title":"Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children","volume":"68","author":"Chencheri","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.07.016_bib123","first-page":"998","article-title":"Early Development of Spinal Deformities in Children Severely Affected with Spinal Muscular Atrophy after Gene Therapy with Onasemnogene Abeparvovec-Preliminary Results","volume":"10","author":"Soini","year":"2023","journal-title":"Children (Basel)"},{"key":"10.1016\/j.ymthe.2024.07.016_bib124","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/ene.15768","article-title":"Italian EAP Working Group. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function","volume":"30","author":"Pane","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib125","doi-asserted-by":"crossref","first-page":"113493","DOI":"10.1016\/j.jpeds.2023.113493","article-title":"Necrotizing Enterocolitis following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series","volume":"260","author":"Gaillard","year":"2023","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ymthe.2024.07.016_bib126","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2023.04.007","article-title":"Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience","volume":"144","author":"Tokatly Latzer","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib127","first-page":"100908","article-title":"Newborn screening for spinal muscular atrophy in Japan: One year of experience","volume":"32","author":"Sawada","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymthe.2024.07.016_bib128","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12883-023-03133-6","article-title":"Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study","volume":"23","author":"Stettner","year":"2023","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib129","first-page":"117","article-title":"Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam","volume":"41","author":"Tosi","year":"2022","journal-title":"Acta Myol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.braindev.2021.12.006","article-title":"Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy","volume":"44","author":"Lee","year":"2022","journal-title":"Brain Dev."},{"key":"10.1016\/j.ymthe.2024.07.016_bib131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2021.01.012","article-title":"Clinical Experience With Gene Therapy in Older Patients With Spinal Muscular Atrophy","volume":"118","author":"Matesanz","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib132","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41434-021-00273-7","article-title":"Gene therapy for spinal muscular atrophy: the Qatari experience","volume":"28","author":"Ali","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.07.016_bib133","doi-asserted-by":"crossref","first-page":"589","DOI":"10.15690\/vsp.v20i6S.2367","article-title":"Short-term safety and efficacy of Onasemnogene Abeparvovec in 10 patients with Spinal Muscular Atrophy: Cohort study","volume":"20","author":"Nevmerzhitskaya","year":"2021","journal-title":"Vopr. Sovr. Pediatr."},{"key":"10.1016\/j.ymthe.2024.07.016_bib134","doi-asserted-by":"crossref","first-page":"1230889","DOI":"10.3389\/fneur.2023.1230889","article-title":"Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment","volume":"14","author":"Nigro","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bjo-2022-321488","article-title":"Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy","volume":"107","author":"Lopez","year":"2023","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2024.07.016_bib136","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41433-022-02262-5","article-title":"Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy","volume":"37","author":"Jalil","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.ymthe.2024.07.016_bib137","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"GENEr8-1 Trial Group. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.016_bib138","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624004714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624004714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T12:47:54Z","timestamp":1758199674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624004714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":137,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1525001624004714"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.07.016","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}